Risk, overall survival, and prognostic analysis of therapy-related acute myeloid leukemia in non-Hodgkin lymphoma survivors.
03 medical and health sciences
0302 clinical medicine
3. Good health
DOI:
10.1200/jco.2022.40.16_suppl.e19037
Publication Date:
2022-06-06T16:55:53Z
AUTHORS (6)
ABSTRACT
e19037 Background: Therapy-related acute myeloid leukemia (tAML) is a serious complication in patients with Non-Hodgkin lymphoma (NHL) exposed to chemotherapy or radiation. tAML demonstrates high risk characteristics and poorer outcomes compared de novo AML. We aimed quantify the of NHL, determine factors associated overall survival (OS) tAML, compare them Methods: Patients histologic diagnosis NHL AML from 2009 2018 were identified Surveillance, Epidemiology, End Results (SEER) 18 database. that developed at least 1 year after was classified as tAML. Multiple primary standardized incidence ratio (SIR) sessions SEER*Stat software (version 8.3.9) used calculate SIR absolute excess (AER) based on - age, sex, race, diagnosis, chemotherapy, radiotherapy, interval diagnosis. The 95% confidence intervals (CI) p-values generated using multivariate Poisson regression model. OS both assessed Kaplan Meier curves then log rank test. roles various evaluated cox proportional hazard regression. Results: A total 373 (N for = 301,903) 23,360 included analysis. More cases ≥70 years (41.1% vs 32.7%, p < 0.001). development significantly higher ages 60 60-69 (SIR 14.0, [CI] 11.79-16.51 4.87, CI 4.00-5.86 2.80, 2.32-3.34, 0.0001). who received more likely develop than non- recipients 8.44, 7.51-9.44 1.75, 1.37-2.21, within 5 5.05, 4.49-5.67 4.39, 3.49-5.45, There no statistically significant difference receipt median 5-year were- 8 months 13.1% 10 27.6% On analysis, not found be an independent predictor (HR 0.93, 0.82-1.04, 0.21). Age ≥60 (age years: HR 1.53, 1.08-2.15, 0.01, age 1.93, 1.40-2.66, 0.001) 1.82, 1.40-2.35, poor subcategory. Conclusions: Our large population-based study shows increased first younger survivors, recipients. Older predispose dismal
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (0)
CITATIONS (0)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....